Written by the DanRuo Hospital medical content team | Last updated: 24 October 2026 · This article is general health information; the specific work-up should be based on an in-person physician assessment.
Transferring good-quality embryos only to see them fail to implant, cycle after cycle, is one of the most frustrating experiences in fertility treatment. Medicine calls this recurrent implantation failure (RIF). It is almost never a single cause but a group of problems that must be investigated systematically - the embryo, the endometrium, immunity and coagulation may all be involved. This article explains the four investigation lines clearly, and sets out how Dan Ruo approaches patients referred to us after repeated failures at other clinics.
Recurrent implantation failure (RIF) usually means: after 2-3 or more transfer cycles of morphologically good-quality embryos, no clinical pregnancy has been achieved. It should be noted that the medical community has not settled on one exact definition (number of failures, embryo standard); here we use the broad definition common in clinical practice.
The key point is not to argue over "how many times counts", but this: repeated failure often indicates that there is an underlying cause that needs to be actively sought, not simply "bad luck". Rather than blindly transferring once more, it is better to investigate systematically first.
The causes of RIF fall broadly into four lines. Investigation usually starts with the non-invasive, most common causes and works progressively deeper:
| Embryonic factors | Common problems: chromosomal aneuploidy, blastocyst culture quality. Usual tools: PGT-A, optimised stimulation and laboratory culture. |
|---|---|
| Endometrium | Common problems: thin endometrium, intrauterine adhesions, chronic endometritis, receptivity. Usual tools: hysteroscopy, endometrial biopsy, ERA and similar. |
| Immune factors | Common problems: antiphospholipid antibodies, NK cells, autoimmunity. Usual tools: reproductive immunology specialist assessment (the evidence is debated). |
| Coagulation factors | Common problems: pre-thrombotic state, endometrial microcirculation. Usual tools: coagulation / thrombophilia screening, with medication only after specialist assessment. |
Embryonic chromosomal aneuploidy is the leading cause of failure to implant and of early miscarriage, and it correlates strongly with female age. The large 2014 study by Franasiak and colleagues of 15,169 blastocyst trophectoderm biopsies (PMID: 24355045) showed euploidy rates of about 60% under age 35, about 35% at 38-40, about 15% at 41-42, and under 10% above 43 (full data in our guide to PGT euploidy rates by age).
The essential point: a good morphology score does not equal normal chromosomes. The embryo grading visible to the eye cannot reflect chromosome status - which is precisely the value of PGT-A: screening out aneuploid embryos before transfer (for how to read the results, see our guide to reading a PGT report). In addition, blastocyst formation quality and the laboratory culture system directly affect the number of usable embryos; the mechanisms behind age-related aneuploidy are covered in our article on why advanced age is fertility's number-one enemy.
Endometrial thickness and pattern: it is generally considered that an endometrium reaching a suitable thickness on transfer day (clinically, 7 mm or above is often used as the reference) with a triple-line pattern favours implantation; a persistently thin endometrium needs its cause investigated (intrauterine adhesions, insufficient blood flow, etc.).
Uterine cavity pathology: intrauterine adhesions, endometrial polyps, submucosal fibroids, uterine septum and similar interfere with implantation; most can be diagnosed and treated by hysteroscopy.
Chronic endometritis: common yet easily overlooked. It can be diagnosed by endometrial biopsy / immunohistochemistry (for example CD138), and after a proper course of antibiotics the implantation rate may improve.
Endometrial receptivity: a displaced window of implantation (WOI) can mean "a good embryo meets the wrong timing". Receptivity tests such as ERA can help individualise transfer timing - but it should be said that these tests are an adjunct, and the clinical evidence is still accumulating.
Immune-related investigation covers antiphospholipid antibodies, antinuclear antibodies, NK cell activity, blocking antibodies, the Th1/Th2 balance and similar.
An objective reminder: the relationship between immune factors and RIF remains debated in the scientific community. Some tests have limited clinical meaning, and the evidence for the corresponding interventions (immunoglobulin, intralipid, steroids and so on) is limited. Such testing and treatment should be evidence-based and carried out under assessment by a reproductive immunology specialist; we do not recommend adopting an "immune package" on your own initiative or overusing medication.
A pre-thrombotic state (thrombophilic tendency) may affect uteroplacental blood flow and endometrial microcirculation. Relevant assessment includes D-dimer, coagulation function, antiphospholipid antibodies, homocysteine and, where necessary, screening for inherited thrombophilia genes.
Whether anticoagulant intervention (such as low-molecular-weight heparin or aspirin) is needed must be decided by a physician after assessment - these drugs have clear indications and bleeding risks. Never self-medicate.
One of Dan Ruo's areas of expertise is handling patients referred after repeated failure at other clinics. The approach is not "switch to more expensive drugs" but to fill in the links that were previously overlooked:
Systematic work-up: at embryo level, PGT-A to screen chromosomes; at cavity / endometrium level, the corresponding assessment; where necessary, immune and coagulation screening added under specialist evaluation.
Individualised stimulation: for advanced age / poor responders, PPOS or luteal-phase stimulation (LPS), or mild stimulation / DuoStim to accumulate embryos.
Laboratory technology reserve: IVM (in vitro maturation of immature oocytes) - Director Peng Wenlin completed Hong Kong's first IVM-assisted pregnancy; and Cryopiece 2.0 single-sperm freezing (post-thaw recovery rate of about 93.3%), improving embryo culture in cases of severe male factor.
Hospital-reported data: a 66.8% success rate among the referred population with repeated failure elsewhere (an overall statistic; individual variation is large - see PGT euploidy rates and success rates). This shows that even after previous failures, there is still a chance once the work-up is redone and the plan adjusted - but actual results require an in-person assessment.
In Dan Ruo's case records, "repeated failure elsewhere → work-up redone → plan adjusted → success" is a common narrative. The common thread is usually not luck but a gap that was filled: patients who should have had PGT-A got chromosome screening; those who needed a cavity check got a hysteroscopy; the stimulation protocol was switched to one better matched to the ovarian response. You can browse the typical cases on our main website to see the approach taken for clients from different backgrounds.
After recurrent implantation failure, many patients ask: "since it hasn't worked so far, can we transfer two at once next time to increase the chance?" From the standpoint of evidence and safety, this is not recommended. Referring to the international society position ASRM Guidance on the number of embryos to transfer (2021; exact stratification follows the latest literature and the hospital's plan), the number of embryos transferred should be decided individually by the physician according to age, embryo quality, whether PGT-A was done and previous cycles. In suitable populations, elective single embryo transfer (eSET) plus elective frozen embryo transfer usually achieves cumulative live birth outcomes comparable to double embryo transfer (DET), with a significantly lower multiple-birth rate. Transferring more embryos means higher twin / higher-order multiple risk - preterm birth, low birth weight, gestational hypertension and diabetes, postpartum haemorrhage and other maternal and infant risks rise directly, and the supposed "insurance" of "one more embryo" is usually cancelled out by these costs.
The key point: the cause of RIF is usually not "too few embryos", but specific links that have not been found and treated - embryo chromosomes, endometrial receptivity, the uterine cavity environment, immunity and coagulation. Working up the four lines systematically is more likely to change the outcome than transferring one extra embryo. When PGT-A has produced a euploid embryo, eSET should be prioritised all the more; see our FAQ on the number of embryos to transfer and eSET, and the dedicated page on multiple pregnancy risk.
When the work-up points to severely limited egg quality or quantity (for example very advanced age, premature ovarian failure, or repeated PGT-A cycles with no euploid embryo available), some patients will, under physician assessment, look into advanced assisted reproductive options. These involve strict legal and ethical frameworks, and regulations differ from country to country.
How many failed transfers count as RIF, and should the full work-up start immediately?
The broad definition commonly used in clinical practice is 2-3 or more transfers of good-quality embryos without a clinical pregnancy. Whether to start a comprehensive work-up immediately depends on age, whether the embryos were PGT-A tested, previous investigations and so on - for older patients, or those whose embryos were never chromosome-screened, simply adding the PGT-A step first may change the outcome. Bring your complete records to a consultation and let the physician decide the order of investigation.
The embryo quality was good - why did it still fail?
A good morphology score only means the embryo "looks good"; it does not mean the chromosomes are normal, nor that the endometrial environment suits implantation. Chromosomal aneuploidy, uterine cavity / endometrial pathology, chronic endometritis, immune and coagulation factors can all cause a morphologically good embryo to fail. This is exactly why a systematic four-line work-up is needed. See also our article on why good-quality embryos can still fail, on the main website.
Is it better to do as many immune / coagulation tests as possible?
No. The relationship between immune factors and RIF remains debated in the scientific community; some tests have limited clinical meaning, and any intervention must be evidence-based. Testing should be selective, under assessment by a reproductive immunology / haematology specialist - avoid blindly buying a "test package" or self-medicating. Heparin, aspirin and similar drugs have clear indications and bleeding risks.
If PGT-A is normal, is success guaranteed?
Not necessarily. PGT-A screens chromosome number and can significantly raise the implantation rate per transfer and reduce miscarriage caused by chromosomal abnormality, but implantation also depends on endometrial receptivity, immune and coagulation factors, the laboratory and transfer technique. A chromosomally normal embryo can still fail for other reasons, so the other three lines must be considered together. See our guide to reading a PGT report.
Would transferring one more embryo make up for the failures?
This is not recommended. Recurrent implantation failure is usually not about "not enough embryos"; the cause lies in specific links that have not been investigated - embryo chromosomes, endometrium / uterine cavity, immunity, coagulation. Transferring more at once only raises the risk of multiples and obstetric complications, and does not proportionally increase the live birth rate per cycle. International societies (ASRM) recommend prioritising eSET in suitable patients, especially when PGT-A has produced a euploid embryo. See section 9 of this page and our FAQ on the number of embryos to transfer and eSET.
Your chances depend on age, ovarian reserve and medical history - start with a free preliminary assessment. Send your test reports for a free preliminary review and a personalised plan with travel advice.
Book a one-to-one fertility assessment Cost guide FAQCall +86 400 618 5161 or email info@incitaivf.com - or add a consultant on WeChat / WhatsApp / Line / Telegram using the QR code at the foot of the page, for pre-travel check-up lists, cost details and scheduling at any time.
This article is general health information and does not constitute medical advice, diagnosis or a guarantee of any outcome. Immune and coagulation investigation and any medication must be evidence-based and carried out under specialist assessment; advanced assisted reproductive options follow an objective, compliant position with no promise of results. Success-rate and similar figures are the hospital's published data; individual variation is large, so please rely on an in-person assessment.
Further reading: PGT euploidy rates and success rates | How to read a PGT report